Results 191 to 200 of about 297,437 (356)

Long‐term effects of metformin on offspring health: A review of current evidence and future directions

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Metformin is widely prescribed for the management of type 2 diabetes mellitus, polycystic ovary syndrome, and gestational diabetes mellitus in pregnancy. Its use is driven by factors including oral administration, lower patient and health system burden and cost, and benefits including lower risk of excess gestational weight gain and ...
Tharaka Mayadunne, Saeede Saadati, Daniel Asmelash, Taitum Mason, Eszter Vanky, Helena Teede, Aya Mousa   +6 more
wiley   +1 more source

Formation of polycystic ovary in mature rats by the long-term administration of human chorionic gonadotropin.

, 1987
Hirotaka Ota, Mineko Fukushima, Masahiro Maki   +2 more
openalex   +2 more sources

Serum immunoreactive leptin concentrations in women with polycystic ovary syndrome. [PDF]

, 1996
Peter R. Brzechffa, A J Jakimiuk, Smita Agarwal, Stacy Weitsman, Richard P. Buyalos, Denis A. Magoffin   +5 more
openalex   +1 more source

Polycystic ovary syndrome: What to say when asked about the chance of pregnancy

Acta Obstetricia et Gynecologica Scandinavica, EarlyView.
Laure Morin‐Papunen, Sari Pelkonen, Terhi Piltonen   +2 more
wiley   +1 more source

Metformin use in women with polycystic ovary syndrome (PCOS): Opportunities, benefits, and clinical challenges

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Metformin, a synthetic biguanide, is widely used to manage type 2 diabetes, and is commonly prescribed in polycystic ovary syndrome (PCOS) to address insulin resistance and associated metabolic and reproductive disturbances. PCOS is characterised by hormonal imbalances such as hyperandrogenism and anovulation, metabolic abnormalities including
Saeede Saadati, Taitum Mason, Rasoul Godini, Eszter Vanky, Helena Teede, Aya Mousa   +5 more
wiley   +1 more source

PMSG-Induced Persistent Estrus in Rats as a Model for Polycystic Ovary Disease

, 1989
Sen-ichi FURUDATE, Takeshi Nakano
openalex   +2 more sources

Selective Insulin Resistance in the Polycystic Ovary Syndrome¹ [PDF]

, 1999
Carol-Beth Book, Andrea Dunaif
openalex   +1 more source

Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention.

Trends in cardiovascular medicine, 2020
O. Osibogun, O. Ogunmoroti, E. Michos
semanticscholar   +1 more source

Glucagon‐like peptide 1 (GLP‐1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The prevalence of diabetes and obesity continues to rise in women of reproductive age, with significant implications for both mother and foetus. Glucagon‐like peptide‐1 receptor agonists are effective treatments of diabetes and obesity. However, no Glucagon‐like peptide‐1 receptor agonists are currently approved for use during pregnancy ...
Claire H. Parker, Craig Slattery, Donal J. Brennan, Carel W. le Roux   +3 more
wiley   +1 more source

The role of macrophages in polycystic ovary syndrome: A review. [PDF]

Medicine (Baltimore)
Li L, Xiao Y, Wen W, Liu Q, Wei L, Liu P, Li M.   +6 more
europepmc   +1 more source